Ambry Genetics' CARE Program Validated for Accuracy in Identifying High-Risk Patients for ...

• Ambry Genetics' CARE Program validated with 99.5% accuracy for hereditary cancer risk assessment.
• The study published in the Journal of the National Comprehensive Cancer Network highlights CARE's effectiveness.
• Ambry Genetics' parent company, Tempus AI, Inc. (TEM, Financial), advances precision medicine through AI.

Ambry Genetics, a subsidiary of Tempus AI, Inc. (TEM), has announced that its AmbryCARE Program® (CARE) successfully validated its accuracy in identifying high-risk patients for hereditary cancer through a peer-reviewed study. The study, published in the...